AB0172 Removal of Pathogenic Anticardiolipin Antibodies in Patients with Systemic Lupus Erythematosus with Antiphospholipid Syndrome

BackgroundA prominent place among rheumatic diseases takes systemic lupus erythematosus (SLE). The most common cause of mortality and the development of permanent disability in this pathology are Lupus-nephritis and Lupus-CNS. The cause of the processes development is tissue damage by circulating antibodies and immune complexes of various specificity. Thus, antibodies to cardiolipin cause a subtype of systemic lupus development with antiphospholipid syndrome (APS), which often can not suppress the disease activity by means of conventional basic therapy.ObjectivesTo create a stable and hemocompatible immobilized granular antigenic drugs (IGAD) to remove antibodies to cardiolipin in APS in SLE patients.Methods63 SLE patients of 16 to 64 years old that meet the criteria of the American Rheumatic Association were examined due to the criteria of phospholipid syndrome according to Hughes G.R.V. and Harris E.N. 1986. [2].To determine the level of anticardiolipin antibodies (ACA) an indirect enzyme-linked immunosorbent method was applied. Magnosorbent was gained by spatially oriented antigen fixation, its stabilization in a carrier taking into account hydrophobic and hydrophilic properties of cardiolipin molecule [3]. Immunoadsorption was performed under in vitro. 20 ml of patient blood containing anticardiolipin, were perfused with a peristaltic micropump (manufactured by LKB, Sweden) at rate of 25ml/hr through a glass column containing 1ml of hemosorbent (IGAD). The ACA level was measured before and after sorption.ResultsThe values of anticardiolipin extinction in healthy individuals was 0.068±0.002. In ACA level analysis, its significant increase was identified (p